Analyst Ratings For Celgene Corporation (NASDAQ:CELG)

Today, Mizuho set its price target on Celgene Corporation (NASDAQ:CELG) to $129.00 per share.

There are 20 Buy Ratings, 12 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Celgene Corporation (NASDAQ:CELG) is Buy with a consensus target price of $124.1852 per share, a potential 37.43% upside.

Some recent analyst ratings include

• 7/27/2018-SunTrust Banks Reiterated Rating of Hold.
• 7/10/2018-Cowen Reiterated Rating of Buy.
• 6/18/2018-Standpoint Research Upgrade from a “Hold ” rating to a ” Buy” rating.
• 5/30/2018-Canaccord Genuity Reiterated Rating of Buy.

Recent Insider Trading Activity For Celgene Corporation (NASDAQ:CELG)
Celgene Corporation (NASDAQ:CELG) has insider ownership of 0.39% and institutional ownership of 75.54%.

• On 6/7/2018 Michael D Casey, Director, sold 13,000 with an average share price of $78.77 per share and the total transaction amounting to $1,024,010.00.
• On 6/4/2018 James J Loughlin, Director, sold 17,750 with an average share price of $78.96 per share and the total transaction amounting to $1,401,540.00.
• On 5/18/2018 Gilla Kaplan, Director, sold 27,750 with an average share price of $78.66 per share and the total transaction amounting to $2,182,815.00.
• On 5/9/2018 Mark J Alles, CEO, bought 1,208 with an average share price of $82.60 per share and the total transaction amounting to $99,780.80.
• On 3/12/2018 James J Loughlin, Director, sold 9,250 with an average share price of $92.01 per share and the total transaction amounting to $851,092.50.
• On 2/23/2018 Ernest Mario, Director, sold 13,370 with an average share price of $94.49 per share and the total transaction amounting to $1,263,331.30.
• On 2/20/2018 Gilla Kaplan, Director, sold 9,250 with an average share price of $94.83 per share and the total transaction amounting to $877,177.50.

About Celgene Corporation (NASDAQ:CELG)
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Recent Trading Activity for Celgene Corporation (NASDAQ:CELG)
Shares of Celgene Corporation closed the previous trading session at 90.18 up +1.27 1.43% with 88.97 shares trading hands.